September 20, 2018 9:37pm

CRSP closed down -$2.90 or -5.59% to $48.99 - ($1.40 above the offering price) after Wednesday's -$1.29 or -1.43% to $51.89

CRSP had 47.59 M shares outstanding and a float of 26.57 M shares, The 52 week change was +172.82%  with a current cash staus of $319.74 M 

BIG deal to close by 9/25/18

CRSP has commenced an underwritten public offering of $200,000,000 of its common shares.

Pricing of an offering of 4,210,526 common shares was set at a public offering price of $47.50 per share, before underwriting discounts. In addition, underwriters have a 30-day option to purchase up to an additional 631,578 common shares at the public offering price less the underwriting discount.

CRISPR Therapeutics anticipates its gross proceeds from the offering, before deducting the underwriter discounts and commissions and other offering expenses, to be approximately $200 million, excluding any exercise of the underwriters’ option to purchase additional shares.


The offering is expected to close on or about September 25, 2018, subject to customary closing conditions.


Goldman Sachs & Co. LLC, Piper Jaffray & Co., Barclays Capital Inc. and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.

Guggenheim Securities, LLC and Needham & Company, LLC are acting as co-managers for the offering.